The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: A therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody

Blood

Volumn 116, Issue 13, 2010, Pages 2286-2294

  Benson Jr , Don M ^a,b   Bakan, Courtney E ^b   Mishra, Anjali ^b   Hofmeister, Craig C ^a,b   Efebera, Yvonne ^a,b   Becknell, Brian ^c   Baiocchi, Robert A ^a,b   Zhang, Jianying ^b   Yu, Jianhua ^b   Smith, Megan K ^a   Greenfield, Carli N ^a   Porcu, Pierluigi ^a,b   Devine, Steven M ^a,b   Rotem Yehudar, Rinat ^d   Lozanski, Gerard ^e   Byrd, John C ^a,b   Caligiuri, Michael A ^a,b  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c NATIONWIDE CHILDREN S HOSPITAL   (United States)

^d CureTech Ltd   (Israel)

^e OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHEMOKINE RECEPTOR CXCR4; CT 011; GAMMA INTERFERON; LENALIDOMIDE; PROGRAMMED DEATH 1 LIGAND 2; PROGRAMMED DEATH 1 RECEPTOR; STROMAL CELL DERIVED FACTOR 1ALPHA; UNCLASSIFIED DRUG;

ANTIGEN ANTIBODY COMPLEX; ARTICLE; CELL ACTIVATION; CELL FUNCTION; CELL ISOLATION; CELL MIGRATION; CONTROLLED STUDY; CYTOTOXICITY; DISEASE ACTIVITY; DOWN REGULATION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 77957701558     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-02-271874     Document Type: Article

References (48)

1. Uchida A, Yagita M, Sugiyama H, Hoshino T, Moore M. Strong natural killer (NK) cell activity in bone marrow of myeloma patients: accelerated maturation of bone marrow NK cells and their interaction with other bone marrow cells. Int J Cancer. 1984;34(3):375-381. (Pubitemid 14032188)
2. Osterborg A, Nilsson B, Bjorkholm M, Holm G, Mellstedt H. Natural killer cell activity in monoclonal gammopathies: relation to disease activity. Eur J Haematol. 1990;45(3):153-157.
3. Gonzalez M, San Miguel JF, Gascon A, et al. Increased expression of natural-killer-associated and activation antigens in multiple myeloma. Am J Hematol. 1992;39(2):84-89.
4. García-Sanz R, Gonzalez M, Orfao A, et al. Analysis of natural killer-associated antigens in peripheral blood and bone marrow of multiple myeloma patients and prognostic implications. Br J Haematol. 1996;93(1):81-88.
5. Frassanito MA, Silvestris F, Cafforio P, Silvestris N, Dammacco F. IgG M-components in active myeloma patients induce a down-regulation of natural killer cell activity. Int J Clin Lab Res. 1997;27(1):48-54.
6. Sawanobori M, Suzuki K, Nakagawa Y, Inoue Y, Utsuyama M, Hirokawa K. Natural killer cell frequency and serum cytokine levels in monoclonal gammopathies: correlation of bone marrow granular lymphocytes to prognosis. Acta Haematol. 1997;98(3):150-154. (Pubitemid 27417619)
7. Nielsen H, Nielsen HJ, Tvede N, et al. Immune dysfunction in multiple myeloma. Reduced natural killer cell activity and increased levels of soluble interleukin-2 receptors. APMIS. 1991;99(4):340-346.
8. + regulatory T cells in patients with multiple myeloma. Blood. 2006;107(10):3940-3949.
9. Tinhofer I, Marschitz I, Henn T, Egle A, Greil R. Expression of a functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma. Blood. 2000;95(2):610-618. (Pubitemid 30041677)
10. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57(1):43-66.
11. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001;98(1):210-216.
12. Shi J, Tricot G, Garg TK, et al., Bortezomib down-regulates the cell surface expression of HLA-class I and enhances natural killer cell mediated lysis of myeloma. Blood. 2008;111(3):1309-1317.
13. Carter L, Fouser LA, Jussif J et al. PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur J Immunol. 2002;32(3):634-643.
14. Keir Me Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Ann Rev Immunol. 2008;26:677-704. (Pubitemid 351600389)
15. Hardy B, Galli M, Rivlin E, Goren L, Novogrodsky A. Activation of human lymphocytes by a monoclonal antibody to B lymphoblastoid cells; molecular mass and distribution of binding protein. Cancer Immunol Immunother. 1995;40(6):376-382.
16. Hardy B, Kovjazin R, Raiter A, Ganor N, Novogrodsky A. A lymphocyte-activating monoclonal antibody induces regression of human tumors in severe combined immunodeficient mice. Proc Natl Acad Sci U S A. 1997;94(11):5756-5760.
17. Hardy B, Yampolski I, Kovjazin R, Galli M, Novogrodsky A. A monoclonal antibody against human B lymphoblastoid cell line induces tumor regression in mice. Cancer Res. 1994;54(22):5793-5796.
18. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 2002;99(19):12293- 12297.
19. Liu J, Hamrouni A, Wolowiec D, Coiteux V, Kuliczkowski K, et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood. 2007;110(1):296-304. (Pubitemid 47026847)
20. Berger R, Rotem-Yehudar R, Slama G, et al. Phase 1 safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res. 2008;14(10):3044-3051.
21. Schafer PH, Gandhi AK, Loveland MA, et al. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther. 2003;305(3):1222-1232.
22. Hayashi T, Hideshima T, Akiyama M, et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol. 2005;128(2):192-203.
23. Zhu D, Corral LG, Fleming YW, Stein B. Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol Immunother. 2008;57(12):1849-1859.
24. Tai YT, Li XF, Catley L, et al. Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical applications. Cancer Res. 2005;65(24):11712-11720.
25. Kinter AL, Godbout EJ, McNally JP, et al. The common gamma-chain cytokines IL-2, IL-7, IL-15 and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol. 2008;181(10):6738-6746.
26. Benson DM Jr., Yu J, Becknell B, et al. Stem cell factor and IL-2/15 combine to enhance MAPK-mediated proliferation of human natural killer cells. Blood. 2009;113(12):2706-2714.
27. Andritsos LA, Johnson AJ, Lozanski G, et al. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol. 2008;26(15):2519-2525.
28. Sheehy ME, McDermott AB, Furlan SN, Klenerman P, Nixon DF. A novel technique for the fluorometric assessment of T lymphocyte antigen specific lysis. J Immunol Methods. 2001;252(1-2):219-220.
29. Lecoeur H, Fevrier M, Garcia S, Riviere Y, Gougeon ML. A novel flow cytometric assay for quantifiation and multiparametric characterization of cell-mediated cytotoxicity. J Immunol Methods. 2001;253(1-2):177-187.
30. Shafer-Weaver KA, Sayers T, Kuhns DB, et al. Evaluating the cytotoxicity of innate immune effectors cells using the GrB ELISPOT assay. J Transl Med. 2004;2(1):31-36.
31. Robertson MJ. Role of chemokines in the biology of human natural killer cells. J Leukoc Biol. 2002;71(2):173-183.
32. Brown JA, Dorfman DM, Ma FR, et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol. 2003;170(3):1257-1266.
33. Strome SE, Dong H, Tamura H, et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res. 2003;63(19):6501-6505.
34. Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, Nishimura M. B7-H1 expression on nonsmall cell lung cancer cells and its relationship with tumor infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res. 2004;10(15):5094-5100. (Pubitemid 39106851)
35. Hamanishi J, Mandai M, Iwasaki M, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A. 2007;104(9):3360-3365.
36. Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198(6):851-862. (Pubitemid 37152922)
37. Romangé F, Andre P, Spee P, et al. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood. 2009;114(13):2667-277.
38. Carbone E, Neri P, Mesuraca M, et al. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood. 2005;105(1):251-258.
39. Jinushi M, Vanneman M, Munshi NC, et al. MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci U S A. 2008;105(4):1285-1290.
40. Zannettino AC, Farrugia AN, Kortesidis A, et al. Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Res. 2005;65(5):1700-1709.
41. Sanz-Rodríguez F, Hidalgo A, Teixido J. Chemokine stromal cell-derived factor 1alpha modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1. Blood. 2001;97(2):346-351. (Pubitemid 32060316)
42. Hideshima T, Chauhan D, Hayashi T, et al. The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma. Mol Cancer Ther. 2002;1(10):539-544.
43. Alsayed Y, Ngo H, Runnels J, et al. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood. 2007;109(7):2708-2717. (Pubitemid 46482062)
44. Beider K, Nagler A, Wald O, et al. Involvement of CXCR4 and IL-2 in the homing and retention of human NK and NKT cells to the bone marrow and spleen of NKD/SCID mice. Blood. 2003;102(6):1951-1958.
45. Parry RV, Chemnitz JM, Frauwirth KA, et al. CTLA-4 and PD-1 receptors inhibit T cell activation by distinct mechanisms. Mol Cell Biol. 2005;25(21):9543-9553.
46. Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol. 2004;173(2):945-954.
47. Bryceson YT, March ME, Ljunggren HG, et al. Activation, coactivation, and costimualation of resting human natural killer cells. Immunol Rev. 2006;214:73-91. (Pubitemid 44707903)
48. El-Sherbiny YM, Meade JL, Holmes TD, et al. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. Cancer Res. 2007;67(18):8444-8449.